|
gptkbp:instanceOf
|
drug
|
|
gptkbp:analyzes
|
submitted
|
|
gptkbp:chemicalFormula
|
C20H22ClN5O2S
|
|
gptkbp:clinicalTrials
|
gptkb:United_States
Europe
ongoing
Phase 1
not yet published
Plexxikon
|
|
gptkbp:collaborations
|
with pharmaceutical companies
|
|
gptkbp:community_service
|
BRAF V600E
|
|
gptkbp:composedOf
|
chemical synthesis
|
|
gptkbp:contraindication
|
cardiovascular issues
liver toxicity
skin lesions
|
|
gptkbp:currentStatus
|
conducted
|
|
gptkbp:date
|
investigational
|
|
gptkbp:developedBy
|
Plexxikon
|
|
gptkbp:discontinued
|
applied for
|
|
gptkbp:dissolved
|
soluble in DMSO
|
|
gptkbp:dosageForm
|
once daily
|
|
gptkbp:drugInterdiction
|
under investigation
under study
|
|
gptkbp:evaluates
|
under investigation
|
|
gptkbp:hasPopulation
|
adults
|
|
gptkbp:hasVariants
|
possible
|
|
gptkbp:healthcare
|
specific mutations required
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
PLX 8747
|
|
gptkbp:isATypeOf
|
1234567-89-0
|
|
gptkbp:ISO639-3
|
planned
|
|
gptkbp:issuedBy
|
oral tablet
|
|
gptkbp:mandates
|
gptkb:melanoma
|
|
gptkbp:market
|
high
|
|
gptkbp:marketedAs
|
not marketed yet
|
|
gptkbp:number_of_stages
|
promising
|
|
gptkbp:patentStatus
|
patented
|
|
gptkbp:productionCompany
|
in development
|
|
gptkbp:regulatoryCompliance
|
not approved yet
|
|
gptkbp:relatedTo
|
gptkb:PLX_4032
|
|
gptkbp:releaseYear
|
2010
|
|
gptkbp:research
|
secured
|
|
gptkbp:research_areas
|
oncology
|
|
gptkbp:researchField
|
oncology
|
|
gptkbp:researchInterest
|
gptkb:University_of_California
yes
published in journals
|
|
gptkbp:route
|
oral
|
|
gptkbp:safetyFeatures
|
under evaluation
|
|
gptkbp:sideEffect
|
fatigue
headache
nausea
diarrhea
rash
|
|
gptkbp:targets
|
yes
BRAF
patients with BRAF mutations
|
|
gptkbp:triggerType
|
BRAF inhibitor
|
|
gptkbp:usedFor
|
cancer treatment
|
|
gptkbp:weight
|
405.93 g/mol
|